# US 2026/0061025 A1 · Polyhomoarginine (PHA) Polymers And Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061025 A1
- Document ID: US20260061025A1
- Status: Published application
- Kind: A1
- Application number: 19/314,948
- Filed: 2025-08-29
- Published: 2026-03-05
- Earliest claimed: 2024-08-30
- Assignees: Singapore Health Services Pte Ltd
- Applicants: Singapore Health Services Pte Ltd
- Inventors: Rajamani LAKSHMINARAYANAN; Jodhbir Singh MEHTA; Tun Aung THET
- Web page: https://patentgrep.com/patent/US20260061025A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 27/02: Ophthalmic agents
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of polyhomoarginine comprising 6-26 homoarginine residues or a pharmaceutically acceptable salt thereof, in the treatment of an infection, wherein the infection is a fungal infection, a bacterial infection or a combination thereof. The present invention also relates to the use of polyhomoarginine comprising 6-26 homoarginine residues or a pharmaceutically acceptable salt thereof in a formulation or in a contact lens.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of treating an infection, wherein the infection is a fungal infection, a bacterial infection or a combination thereof, comprising administering a polyhomoarginine comprising 6-26 homoarginine residues or a pharmaceutically acceptable salt thereof to a subject.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the polyhomoarginine comprises 8-12 homoarginine residues, preferably 10 homoarginine residues, or wherein the polyhomoarginine has an average molecular weight in the range of about 2,000 to about 6,000 Da.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the polyhomoarginine comprises L-homoarginine and/or D-homoarginine, or wherein the polyhomoarginine is optically pure, or wherein the polyhomoarginine consists only of L-homoarginine.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the fungal infection is caused by a fungus selected from the group consisting of Candida species, Fusarium species, Aspergillus species, Cryptococcus species and any mixture thereof, or the fungal infection is caused by a fungus selected from the group consisting of C. albicans, C. parapsilosis, C. tropicalis, C. guillermondii, C. krusei, F. solani, F. dimerum, F. oxysporum, F. sacchari, and F. verticillioides, F. polyphialidicum, A. flavus, A. effusus, A. tamarii, A. sydowii, A. protuberus and A. terreus and any mixture thereof.

### Claim 25 (depends on 21)

The method according to claim 21, wherein the bacterial infection is caused by gram-positive bacteria and/or gram-negative bacteria, or the bacterial infection is caused by a bacteria selected from the group consisting of Staphylococcus species, Streptococcus species, Pseudomonas species, Enterobacteriaceae, and any mixture thereof, or the bacterial infection is caused by a bacteria selected from the group consisting of S. aureus, Methicillin-resistant S. aureus, S. epidermidis, S. pneumoniae, P. aeruginosa, and any mixture thereof.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the infection further comprises an infection caused by an amoeba, preferably Acanthamoeba species.

### Claim 27 (depends on 21)

The method according to claim 21, wherein the infection is an infection of the skin, or the infection is an infection of the eye, or the infection is an infection of the cornea of the eye, or the infection is keratitis.

### Claim 28 (depends on 21)

The method according to claim 21, wherein the polyhomoarginine is to be administered topically, intrastromally, intracamerally, or by subconjunctival injection.

### Claim 29 (depends on 21)

The method according to claim 21, wherein the polyhomoarginine is to be administered in a formulation having a concentration in the range of 50 μg/mL to 50 mg/mL, or the polyhomoarginine is to be administered 1 to 12 times per day.

### Claim 30 (depends on 21)

The method according to claim 21, comprising a further antimicrobial agent, preferably an antibacterial agent or an antifungal agent, preferably wherein the further antimicrobial agent is selected from the group consisting of amphotericin B, natamycin, fluconazole, ketaconazole, voriconazole, miconazole, luliconazole and any mixture thereof.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the further antimicrobial agent is selected from the group consisting of amphotericin B, natamycin, fluconazole, ketaconazole, voriconazole, miconazole, luliconazole and any mixture thereof.

### Claim 32

A contact lens comprising polyhomoarginine comprising 6-26 homoarginine residues or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 32)

A method of treating an infection, wherein the infection is a fungal infection, a bacterial infection or a combination thereof, comprising applying the contact lens of claim 32 to an eye of a subject.
